Loading…
Viking Therapeutics, Inc. is projected to rise to $45.34 by 2027, a +37% move from its current price of $33.11. VKTX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $32.22 | $33.13 | $34.06 | +0.05% |
| Aug 2 | $31.87 | $33.15 | $34.47 | +0.11% |
| Aug 3 | $31.60 | $33.16 | $34.80 | +0.16% |
| Aug 4 | $31.39 | $33.18 | $35.08 | +0.21% |
| Aug 5 | $31.20 | $33.20 | $35.33 | +0.27% |
| Aug 6 | $31.03 | $33.22 | $35.56 | +0.32% |
| Aug 7 | $30.88 | $33.23 | $35.77 | +0.38% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $30.88 | $33.23 | $35.77 | +0.38% |
| Week 2 | $30.06 | $33.36 | $37.02 | +0.75% |
| Week 3 | $29.48 | $33.49 | $38.03 | +1.13% |
| Week 4 | $29.01 | $33.61 | $38.94 | +1.51% |
| Week 5 | $28.62 | $33.74 | $39.77 | +1.90% |
| Week 6 | $28.28 | $33.86 | $40.55 | +2.28% |
| Week 7 | $27.98 | $33.99 | $41.29 | +2.66% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
The company develops VK5211, VK0612, VK2735, and VK0214, all advancing in various clinical programs. The company was incorporated in 2012 and is headquartered in San Diego, California.
VKTX trades in the Healthcare sector with a current price of $35.39, a market cap of $4.11B, and a rank of 1490. These fundamentals place Viking Therapeutics among mid-cap biotechnology listings. The 30-day forecast shows a neutral near-term bias, with a 2026 average price of $35.39, a low of $26.29, and a high of $51.80; the forecast also shows a neutral sentiment and an ROI of 0.0.
From 2027 onward, the outlook becomes increasingly bullish as average prices rise and ROIs expand.
A major floor 29.5% below — a decisive break under it would weaken the trend.
The nearest floor, 8.5% below — buyers have tended to step in here.
The nearest ceiling, 27.2% above — a clean break opens room to run.
A major ceiling 42.0% above — clearing it would confirm fresh momentum.
Key VKTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of VKTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $34.01 | Sell | $34.05 | Sell |
| MA 10 | $35.42 | Sell | $35.05 | Sell |
| MA 20 | $37.13 | Sell | $35.70 | Sell |
| MA 50 | $33.94 | Sell | $34.85 | Sell |
| MA 100 | $33.57 | Sell | $33.96 | Sell |
| MA 200 | $33.81 | Sell | $33.59 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 39.81 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -141.75 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.78 | Sell |
| ROC (12) | -12.80 | Sell |
| Bollinger %B (20,2) | 0.08 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.25 | Buy |
| Awesome (5,34) | -1.76 | Sell |
| Ultimate (7,14,28) | 15.07 | Buy |
| Momentum (10) | -3.26 | Sell |
| Aroon Osc (25) | -68.00 | Sell |
| Hull MA (9) | 32.87 | Buy |
| ADX (14) | 17.06 | Neutral |
| ATR (14) | 0.94 | Info |
The 30-day technical picture is NEUTRAL with RSI14 at 50, and moving averages showing modest near-term support around the mid-$30s. The SMA50 is $33.62 and the SMA200 is $33.78, indicating a tight price band around the current level. Support is indicated at $27.75 and resistance at $42.13, with a 30-day price range from $28.77 to $43.53.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $26.29 | $33.11 | $46.58 | 0% | Neutral | |
| $36.09 | $45.34 | $60.24 | +37% | Bullish | |
| $38.89 | $50.28 | $69.41 | +52% | Bullish | |
| $38.80 | $51.36 | $73.04 | +55% | Bullish | |
| $40.64 | $54.94 | $80.09 | +66% | Bullish | |
| $43.14 | $59.44 | $88.55 | +80% | Bullish | |
| $45.44 | $63.74 | $96.82 | +93% | Bullish | |
| $55.24 | $78.78 | $121.79 | +138% | Bullish | |
| $60.26 | $87.31 | $137.17 | +164% | Bullish | |
| $62.38 | $91.76 | $146.34 | +177% | Bullish | |
| $85.21 | $134.27 | $227.98 | +306% | Bullish | |
| $134.57 | $238.70 | $443.99 | +621% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $26.29 | $33.11 | $38.60 | +0.00% |
| August 2026 | $28.37 | $33.31 | $40.03 | +0.60% |
| September 2026 | $29.36 | $34.77 | $42.36 | +4.39% |
| October 2026 | $29.66 | $35.36 | $43.55 | +1.71% |
| November 2026 | $29.56 | $35.44 | $44.02 | +0.21% |
| December 2026 | $30.88 | $37.21 | $46.58 | +5.00% |
Click any year to see its month-by-month VKTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, VKTX could reach as high as $46.58, with a base case around $33.11 and support toward $26.29 — roughly 0% from $33.11. Price action looks broadly range-bound.
Expect VKTX to range from $36.09 to $60.24 through 2027. The $45.34 average target implies a +37% move from current prices. That is up +37% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The VKTX price prediction for 2028 points to an average of $50.28 (low $38.89, high $69.41) — a potential gain of +52% on today's $33.11. Momentum favours further upside here.
In 2029, VKTX is projected to trade between $38.80 and $73.04, averaging $51.36 — a potential gain of +55% from today's $33.11. That is up +2% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Viking Therapeutics, Inc.'s 2030 outlook centres on $54.94, within a $40.64 to $80.09 range. That is up +7% on the projected 2029 average. That marks a +66% change versus current levels. Momentum favours further upside here.
By 2031, VKTX could reach as high as $88.55, with a base case around $59.44 and support toward $43.14 — roughly +80% from $33.11. Buyers look set to stay in control over this stretch.
Expect VKTX to range from $45.44 to $96.82 through 2032. The $63.74 average target implies a +93% move from current prices. That is up +7% on the projected 2031 average. Momentum favours further upside here.
The VKTX price prediction for 2033 points to an average of $78.78 (low $55.24, high $121.79) — a potential gain of +138% on today's $33.11. Buyers look set to stay in control over this stretch.
In 2034, VKTX is projected to trade between $60.26 and $137.17, averaging $87.31 — a potential gain of +164% from today's $33.11. That is up +11% on the projected 2033 average. Momentum favours further upside here.
Viking Therapeutics, Inc.'s 2035 outlook centres on $91.76, within a $62.38 to $146.34 range. That is up +5% on the projected 2034 average. That marks a +177% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, VKTX could reach as high as $227.98, with a base case around $134.27 and support toward $85.21 — roughly +306% from $33.11. Momentum favours further upside here.
Expect VKTX to range from $134.57 to $443.99 through 2050. The $238.70 average target implies a +621% move from current prices. That is up +78% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in VKTX today (≈ 30.202356 VKTX) could be worth
$7,209.39
+$6,209.39 (+621%) by 2050 · US Dollar
Based on the average projected VKTX price of $238.7 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in VKTXwould be worth at today's price.
$1,000 invested in VKTX on Jul 30, 2025 (≈ 29.664789 VKTX) would be worth
$982.2
-$17.8 (-1.8%) today · 0.98× · US Dollar
Based on a VKTX entry price of $33.71 vs. today's $33.11.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $35.39 | $935.58 | -6.4% |
| 1 month ago | $39.01 | $848.76 | -15.1% |
| 3 months ago | $30 | $1,103.67 | +10.4% |
| 6 months ago | $29.04 | $1,140.15 | +14.0% |
| 1 year ago | $33.71 | $982.2 | -1.8% |
| All time (5.0y) ago | $6.06 | $5,463.7 | +446.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our VKTX forecast.
Our base-case forecast reaches $66.00 around 2033.
Implied market cap at $66.00: $7.7B
The multi-year forecast shows a bullish trajectory after 2026, with rising averages and ROIs through 2030 and beyond. For 2030, the average price is $59.56 and the ROI is 68.3, suggesting meaningful appreciation from today’s level. Longer term, 2040 projects an average of $150.37 with an ROI of 324.9, and 2050 projects an average of $269.20 with an ROI of 660.7, underscoring a strong growth path if the forecasts materialize.
These are estimates and not guarantees, and actual results may vary with clinical, regulatory, and market developments.
Tap a question to reveal the answer.
2030 avg $59.56; min $43.03; max $89.18; ROI 68.3; sentiment BULLISH.
The forecast shows a bullish bias beginning in 2027 with rising average prices (e.g., 2027 avg $49.59, 2030 avg $59.56) and higher ROIs (up to 68.3% in 2030 and higher thereafter), after a neutral 2026. These are estimates, not guarantees.
Yes, the forecast shows a path where the 2032 max is $110.09 and 2033 max is $139.32, with 2031 max $99.20, indicating crossing $100 could occur in 2032 or 2033 depending on market conditions.
Current price is $35.39 and market cap is $4.11B.
Long-term forecasts show 2030 avg $59.56 (ROI 68.3), 2040 avg $150.37 (ROI 324.9), and 2050 avg $269.20 (ROI 660.7), with bullish sentiment indicated across these horizons.
Viking Therapeutics, Inc. Community Discussion
0Share your Viking Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.